News

New Manufacturing and Advanced R&D Facility Opens in Charlottesville, VA, Making Plant-Based, Prebiotic Sugar Alternative Accessible for All

A new manufacturing facility has officially opened its doors in Charlottesville, VA, dedicated to the production of tagatose, a sweet plant-based material with numerous health benefits. The facility, owned and operated by Bonumose, will produce high-quality tagatose for use in a wide range of food and beverage products.

Tagatose is 90% as sweet as table sugar, but with 62% fewer calories than regular sugar, with no bitter aftertaste. It is also ultra-low on the glycemic index, making it a suitable sweetener for people with diabetes or anyone watching their health. Tagatose also has prebiotic properties, promoting the growth of beneficial bacteria in the gut. Tagatose has been certified as non-GMO, ketogenic, and kosher, making it a welcome ingredient in many diets.

Using enzymes and a plant-based starch, alongside a proprietary process, Bonumose is able to reduce the cost of this sugar alternative, making it affordable for the global mass market.

The new 50,000-square-foot facility, located at 1500 State Farm Blvd, uses standard equipment coupled with a patented enzymatic conversion process to ensure the highest quality and consistency of tagatose production. An equity investment co-led by sweetener company ASR Group and The Hershey Company supported the facility, as did a loan from X-Caliber Rural Capital. So far, Bonumose has brought more than 30 jobs to the Charlottesville community.

“I am excited to celebrate the opening of Bonumose’s state-of-the-art production and research facility in Albemarle County,” said Governor Glenn Youngkin. “This pioneer in the rare sugar industry will utilize its expanded new space to produce an innovative product that is changing the way we consume sugar, providing a healthier alternative without sacrificing taste. Bonumose is a tremendous Virginia success story, and we look forward to a continued partnership with the company in its next chapter of growth.”

“Opening this new facility is an important milestone on the road to bringing the benefits of tagatose to the public,” said Ed Rogers, CEO of Bonumose. “More so than any other alternative to sugar and high-fructose corn syrup, we believe tagatose can enable better-for-you foods that are on parity for palatability and price with consumer favorites.”

Bonumose plans to expand production in the near future. In addition to tagatose, the Virginia facility can produce other ingredients that are in Bonumose’s development pipeline. Major food and beverage brands are evaluating tagatose for their products to respond to consumer demand for reducing sugars without sacrificing taste or texture.

“We are working to encourage broad-market adoption of this pure granulated tagatose as a beneficial sugar alternative,” added Rogers. “Tagatose has everything you love about sugar with better health benefits.”

For more information about tagatose and the new manufacturing facility, please visit www.bonumose.com.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep